Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

Moderna’s stock price has taken a beating over the past six months, shedding 33.6% of its value and falling to $26.85 per share. This was partly due to its softer quarterly results and may have ...

Moderna's Q1 2022 financial performance was better than expected, but MRNA didn't raise full-year 2022 guidance. See if MRNA stock is a buy, sell, or hold.

Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion ...

Moderna (MRNA-1.32%), a leader in the field of messenger RNA (mRNA)-based vaccines and therapeutics, is a prime example. The company's stock price skyrocketed in 2021, thanks to the strong sales ...

Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock dropped even further after lowering its expected revenue range for 2025 ...

A Look at Moderna's Recent Stock Price Performance Over the past month, the stock has seen a decline of 14.2% in its value, whereas the Zacks S&P 500 composite has posted a decrease of 0.5%.